Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in EGFR wild-type advanced non-squamous NSCLC after chemotherapy failure
CTR20150124Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2015
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Hengrui Therapeutics. Started Mar 2015; status: active.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20150124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150124.